Physician profile
Sonja M Marcic
NPI 1700823192
$3,999.88
in general payments reported to CMS, 2019-2025
24 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $355 · 2021: $222 · 2022: $373 · 2023: $782 · 2024: $979 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,255.21 |
| Education | $169.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $713.20 | 2019-2025 | Lokelma, Farxiga |
| Travere Therapeutics, INC. | $698.84 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $437.77 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $413.53 | 2019-2025 | Jynarque |
| Amgen INC. | $258.36 | 2022-2025 | Krystexxa, Tavneos |
| Akebia Therapeutics INC | $209.98 | 2019-2022 | |
| Horizon Therapeutics Plc | $195.47 | 2021-2023 | Krystexxa |
| Ardelyx, INC. | $169.79 | 2025 | Xphozah 30 Mg, Ibsrela |
| Ani Pharmaceuticals, INC. | $125.01 | 2022-2024 | Purified Cortrophin Gel |
| Veloxis Pharmaceuticals, INC. | $115.96 | 2019 | |
| Calliditas Therapeutics US INC. | $107.77 | 2022-2025 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $90.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $80.02 | 2023-2025 | |
| Ultragenyx Pharmaceutical INC. | $72.75 | 2023-2024 | Crysvita |
| Vifor Pharma, INC. | $52.80 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $47.45 | 2022-2025 | Velphoro |
| Mallinckrodt Hospital Products INC. | $42.08 | 2023 | Acthar |
| Alexion Pharmaceuticals, INC. | $37.07 | 2024 | Ultomiris |
| Mallinckrodt Enterprises LLC | $32.40 | 2019 | |
| Kyowa Kirin, INC. | $24.91 | 2025 | |
| Baxter Healthcare | $21.83 | 2023 | Renal - Pd |
| Lilly USA, LLC | $19.28 | 2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $14.13 | 2023 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonja Marcic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.